comprehensive -WSS

comprehensive

author：explore 2025-10-03 00:37:43 - browse：7495

The term “excited delirium” has been used for years by law enforcement and other first responders, including health care workers, to describe people who exhibit behavior that is considered “out of control.” This diagnosis has been applied again and again, even posthumously, as a justification for extreme, and sometimes deadly, interventions by law enforcement. It came up most recently in the trials of two police officers accused of causing the death of Elijah McClain, a Colorado man; both officers were acquitted this week.

But excited delirium is not an evidence-based medical diagnosis. The American College of Emergency Physicians recently withdrew a 2009 white paper endorsing the concept, and California has banned it as a cause of death. Other states may follow suit.

On this week’s episode, we are joined by Utsha G. Khatri, an assistant professor of emergency medicine and population health and policy at the Icahn School of Medicine at Mount Sinai, and emergency physician Brooks Walsh, who was involved with the campaign to get ACEP to withdraw the 2009 white paper. Khatri and Walsh speak about why the “excited delirium” label is both unnecessary and dangerous.

“We recognize that some patients are confused. They’re not thinking clearly they might have risk for becoming violent either toward themselves or towards other staff,” Khatri said. “It is our job not just to keep them and everyone else safe, but also to most importantly find out what is causing them to act in this way.”

You can read Khatri’s First Opinion essay on the end of “excited delirium” here.

Be sure to sign up for the weekly “First Opinion Podcast” on Apple Podcasts, Spotify, Google Play, or wherever you get your podcasts.

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： Lilly's Alzheimer's drug donanemab backed by FDA advisers

WSS

Listen: A conversation with researcher Kevin Esvelt on biosecurity

Moderna says combo Covid

Cytokinetics sells Royalty Pharma a share of its heart drug for up to $575M

Scrutiny of post

Lilly's Alzheimer's drug donanemab backed by FDA advisers

Lilly's Alzheimer's drug donanemab backed by FDA advisers

focus

comprehensive

knowledge

Novavax promises a turnaround & Lilly roils the obesity market

Moderna says combo Covid

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Scrutiny of post

Dobbs anniversary: the lost opportunity of abortion as health care

Digital health: a case of mistaken identity

Psychedelics group wrestles with new pharma identity

Study: Why relieving medical debt did not improve financial outcomes

How one medical school became remarkably diverse

Liver decline slowed by off

Wikipedia

How the BIOSECURE Act is already affecting U.S., Chinese life science firms

H5N1 bird flu outbreak: Second human case reported, in Michigan

Liver decline slowed by off

FDA reviewers ask if approval of Lilly’s Alzheimer’s drug should be restricted

Moderna says combo Covid

Coercive sterilizations revealed by STAT prompt outrage

entertainment

focus

explore

focus